Opens in a new tab
For licensed clinics onlyRefrigerated lines shipped cold
1-800-630-9757Open hoursMonday to Friday, 9am to 6pm ETBook a call with MWS

Bayer

40 mg/1mL1mL VialRx requiredIn stock

Order EYLEA® Non-English Online for Clinics

AFLIBERCEPT

Free shipping on orders over $800

5% off your first order, applied at checkout

QuantityPrice per vial
This option is currently unavailable. Please choose another.
Treatment cost and margin plannerPlanning tool

Enter your own figures: the vials you use per treatment and what you charge per treatment. The table shows your product cost and margin per treatment at each quantity price. It does not suggest doses, prices or treatments.

QuantityPrice per packCost per unitCost per treatmentMargin per treatment

Uses today's prices for the selected option before shipping and any other costs. Your figures stay in your browser.

Storage
Room Temperature (2℃~25℃)
  • Ships within 24–48 hours

    Delivery typically 48–72 hours after shipping, up to 5–7 business days depending on origin and customs. Tracking is emailed when your order ships.

  • Warm or damaged on arrival?

    Send us photos or a video. We investigate and arrange a replacement where needed.

  • Licence checks

    Licences are checked against the state board and the NPI registry.

  • 100% genuine products

    In original manufacturer packaging, with lot numbers for full traceability. Lot numbers are shown on your packing slip and invoice.

Rated 5/5 by our clinic customers

250 active clinics · Supplying clinics since 2013

“Everything has been easy from ordering to delivery. The prices are good, orders arrive quickly, and the customer service has been great. I would definitely order from MWS again.”
Alex B., NP
We acceptVisa, Mastercard and American Express

Customer service team

Monday to Friday, 9am to 6pm ET

Eylea® (Non-English)

$1,499.00
You save

Add to order

Specifications at a glance

Manufacturer
Bayer
Generic name
AFLIBERCEPT
Size / strength
40 mg/1mL
Package content
1mL Vial
Drug class
Biologic
Drug type
Prescription Medication
Storage
Room Temperature (2℃~25℃)
Prescription
Rx required. Supplied to licensed practitioners only.

Product documents

Lot or batch numbers can be verified with the manufacturer, where applicable. They are also shown on your packing slip and invoice.

About Eylea® (Non-English)

EYLEA® (Non-English) is aflibercept, an anti-VEGF ophthalmic medicine supplied as a vial for intravitreal injection by trained eye-care professionals. Licensed clinics and healthcare professionals can order EYLEA® Non-English online for professional retina workflows, with attention to the 40 mg/mL vial presentation and non-English carton language. Because this is a refrigerated biologic used in treatment-room procedures, staff should align strength, quantity, storage capacity, and documentation before purchase.

This EYLEA® presentation is intended for clinical supply programs that can manage professional-use medicines, sterile preparation, and language-variant inventory controls. The non-English pack should fit your clinic’s internal labelling process, receiving checklist, staff training, and recordkeeping expectations before it enters stock.

EYLEA® Price, Vial Selection, and Clinic Ordering

EYLEA® price for clinics should be evaluated against the vial concentration, carton language, quantity, expiry dating, and storage requirements. If your purchasing team handles more than one EYLEA® item, match the active ingredient, vial wording, and label language rather than relying on the brand name alone. This helps prevent mix-ups between English and non-English packs or between different aflibercept presentations.

The current order total reflects the quantity chosen during checkout and any product-specific price shown for the vial. A practical clinic comparison includes more than acquisition cost. Receiving controls, lot capture, refrigerated storage, staff readability, and treatment-room identification all affect whether the product fits your workflow.

MedWholesaleSupplies serves licensed clinics and healthcare professionals with brand-name medical products sourced through vetted distributors and verified supply channels. For this ophthalmology product, your team should make the cart match the intended aflibercept item, the receiving location, and the internal purchase record before submission.

  • Product identity: EYLEA® with aflibercept as the active ingredient.
  • Strength wording: 40 mg/mL when shown for this vial.
  • Vial content wording: 4 mg/100 microliter may appear for the vial contents.
  • Label language: non-English carton or pack information.
  • Handling plan: refrigerated storage and protected inventory flow.

Quick tip: Assign one staff member to reconcile the order record, carton language, and receiving log.

What EYLEA® Is Used For in Ophthalmology

EYLEA® contains aflibercept, a vascular endothelial growth factor inhibitor. In plain terms, anti-VEGF treatment blocks VEGF, a signal involved in abnormal blood vessel growth and fluid leakage in the retina. The medicine is administered by intravitreal injection, meaning injection into the eye’s vitreous cavity.

Aflibercept is used in retina care for conditions in which abnormal blood vessels or retinal fluid can threaten vision. Authorised uses may include neovascular age-related macular degeneration, often called wet AMD, diabetic macular edema, macular edema following retinal vein occlusion, diabetic retinopathy, and other approved retinal indications depending on the market and applicable product label. Treatment selection, dose interval, and patient suitability belong with the ophthalmologist and the approved prescribing information.

Procurement teams should translate that clinical context into accurate stock control. Retina practices may carry several anti-VEGF medicines with different strengths, dose schedules, vial or syringe formats, storage rules, and documentation requirements. The Ophthalmology Products category can help staff review related professional eye-care supplies while keeping EYLEA® identification separate from unrelated inventory.

Strength, Vial Presentation, and Label-Language Checks

This non-English EYLEA® item is associated with a 40 mg/mL vial presentation. Product wording may also reference 4 mg/100 microliter vial contents. Concentration, total vial contents, and administered dose are different concepts, so purchasing records should preserve the exact wording used on the carton and internal inventory entry.

Non-English packaging can be appropriate for clinics that have SOPs for language-variant medical stock. Staff must still be able to identify the brand, active ingredient, concentration, lot or batch number, expiry date, manufacturer information, and storage instructions. If your audit process, treatment-room workflow, or staff training materials require English carton text, review the English-labelled EYLEA® alternative before finalizing the purchase.

Ordering detailClinic check
Active ingredientAflibercept
Medicine classAnti-VEGF ophthalmic biologic
Concentration40 mg/mL when shown for this vial
PresentationVial for intravitreal injection
Label languageNon-English packaging or carton information
Use settingRetina clinic or ophthalmology treatment workflow

Why it matters: Accurate language and strength records reduce avoidable receiving corrections and treatment-room delays.

Storage, Temperature Control, and Receiving Workflow

EYLEA® is a biologic medicine and should be stored according to the applicable carton and product information. Standard aflibercept labelling generally calls for refrigerated storage at 2°C to 8°C, protection from light, and avoidance of freezing. Your clinic should follow the instructions supplied with the pack received.

Plan refrigerator capacity before placing larger clinic orders, especially if your practice also stores other retina therapies. Temperature-controlled handling when required and tracked US delivery should be matched to your receiving hours, inspection process, and cold-storage capacity. Once received, staff should inspect the outer carton, lot information, expiry date, and any temperature-sensitive handling notes before moving the vial into clinic stock.

Inventory systems should identify this item as a non-English presentation, not simply as EYLEA®. Clear naming helps future stock counts, treatment-room pulls, and audit records distinguish it from other aflibercept products. If your clinic manages broader regulated stock, the Pharmaceuticals category may support cross-department product-list review.

Administration and Treatment-Room Fit

EYLEA® is administered by intravitreal injection under aseptic ophthalmic conditions. It is not a general injectable for non-specialist office use. The clinician performing the procedure should be trained in sterile preparation, intravitreal technique, ocular assessment, and post-injection monitoring.

Procurement staff do not set treatment intervals, but product presentation still affects clinical workflow. A vial may require specific preparation steps, sterile supplies, waste handling, documentation, and a reliable process for confirming key carton information before the procedure day. The non-English label adds another reason to use a consistent receiving and treatment-room verification process.

Practices may organize anti-VEGF inventory by brand, active ingredient, physician preference, indication, or appointment schedule. Consistent naming reduces the chance of selecting the wrong item from refrigerated stock. For broader brand-specific navigation, the Eylea Brand Collection helps teams review available EYLEA® items without mixing them with unrelated ophthalmology products.

Safety, Contraindications, and Monitoring

EYLEA® should not be used in patients with ocular or periocular infection, active severe intraocular inflammation, or known hypersensitivity to aflibercept or any component of the medicine. These contraindications matter operationally because the product should be stocked and released only within a controlled ophthalmology workflow. Final patient selection remains the responsibility of the treating specialist.

Serious injection-related risks can include endophthalmitis, retinal detachment, traumatic cataract, and increases in intraocular pressure. Clinics should have procedures for post-injection monitoring and urgent escalation if patients report eye pain, increasing redness, light sensitivity, or sudden vision changes. Arterial thromboembolic events have also been reported with intravitreal VEGF inhibitors, so cardiovascular history may be part of the clinician’s assessment.

Common ocular adverse effects reported with aflibercept products may include conjunctival hemorrhage, eye pain, vitreous floaters, cataract, and increased intraocular pressure. Some events are associated with the injection procedure rather than aflibercept alone. Safe use depends on accurate product identification, aseptic technique, sterile supplies, monitoring protocols, and clear documentation.

Drug-interaction considerations for anti-VEGF treatment are generally handled by the ophthalmology team. Procurement can support safety by ensuring the exact EYLEA® vial, concentration, label language, and quantity are available for scheduled clinic sessions. Substitution between anti-VEGF medicines should follow clinician direction, not inventory convenience.

Related Retina Options and Clinical Comparisons

Another name for EYLEA® is aflibercept, the active ingredient. That does not make every aflibercept-related or anti-VEGF item interchangeable. Products may differ by concentration, labelled indication, dose schedule, vial or syringe format, approved market information, and handling requirements.

Clinics asking about alternatives to EYLEA® should separate clinical choice from purchasing logistics. Vabysmo® is another retina injection used in anti-VEGF-related treatment pathways, but it contains a different active ingredient and should be selected only when clinically intended. The Vabysmo injection product entry can help procurement teams identify a separate retina medicine without treating it as an automatic substitute.

Staff who need clinical background on newer aflibercept presentations can read EYLEA HD and retinal disease context. Keep educational review separate from the purchase record for this 40 mg/mL non-English vial. For other eye-care medicines outside retina injection workflows, Tobradex ophthalmic suspension information may help teams distinguish topical infection-related products from intravitreal biologics.

Pre-Checkout Checklist for Licensed Clinics

Before submitting an EYLEA® order, make sure the product identity and operational details align with the clinical purchase request. The most important checks are practical: brand, active ingredient, concentration, vial content wording, quantity, label language, refrigerated storage space, and receiving responsibilities.

  1. Match the clinical record: align EYLEA® and aflibercept with the intended retina medicine.
  2. Confirm vial wording: record 40 mg/mL and any 4 mg/100 microliter language accurately.
  3. Review language controls: ensure staff can identify essential carton and vial information.
  4. Prepare cold storage: reserve refrigerator space before the shipment arrives.
  5. Document receipt: capture lot, expiry, carton condition, and storage notes.
  6. Escalate uncertainty: pause if the vial, language variant, or quantity does not match the order record.

A disciplined receiving process protects inventory accuracy and treatment-room readiness. It also helps clinics maintain clean records when more than one anti-VEGF product or label-language variant is stocked.

Authoritative Sources

Use official medical references for clinical protocols, staff training, and treatment decisions. This product copy supports procurement and product identification; it does not replace approved prescribing information.

This content is for informational purposes only and is not a substitute for professional medical advice.

Questions clinics ask

EYLEA® Non-English is an aflibercept intravitreal injection supplied with non-English packaging or carton information. It is used in professional retina-care workflows and should be handled by licensed clinics with appropriate storage, documentation, and treatment-room controls.

40 mg/mL describes the concentration shown for this vial presentation. Vial-content wording such as 4 mg/100 microliter may also appear. Clinics should record concentration, vial contents, and carton language exactly as shown and follow the approved product information for clinical dosing.

EYLEA® should not be used in patients with ocular or periocular infection, active severe intraocular inflammation, or known hypersensitivity to aflibercept or product components. Individual suitability must be determined by the treating ophthalmology specialist.

EYLEA® should be stored according to the supplied carton and product information. Standard aflibercept labelling generally requires refrigeration at 2°C to 8°C, protection from light, and no freezing. Receiving staff should document lot, expiry, carton condition, and storage status.

Aflibercept is the active ingredient in EYLEA®. The names are related, but clinics should still match the exact brand, concentration, vial presentation, and label language before purchase or treatment-room use.

Substitution should be directed by the treating clinician. Other retina injections may have different active ingredients, indications, strengths, preparation steps, and dosing schedules, so procurement teams should not substitute based on inventory availability alone.

MWS Customer Service Team

Ordering in volume or opening a clinic account? Talk to us.

Our customer service team helps you choose the right pack, label option and quantity for your clinic, and sets up your first order.

Monday to Friday, 9am to 6pm ET

Why clinics order from MWS

  • Built for licensed clinics

    Licences are checked against the state board and the NPI registry.

  • Every pack option named

    Each option names its dosage and pack size, so you know which pack you are ordering.

  • Volume pricing up front

    Quantity tiers are shown on the product, before you order.

  • Cold-chain packing

    Refrigerated lines ship in thermo-packaging with enough ice packs to hold temperature for up to 10 days.

“The customer care team was very efficient in offering hand-held guidance to choose the most cost-effective options.”
Dr Tukba Yalcin, Lumiere Aesthetics

Related reading